INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Regulation FD Disclosure

11

INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure: Corporate Presentation

On June 19, 2017, the Company provided an update to its corporate
presentation. The presentation will be available on the Companys
website atwww.innovuspharma.comand filed herewith as Exhibit
99.1.
The information set forth in this Item 7.01, including Exhibit
99.1, is being furnished to Item 7.01 and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), or otherwise subject to
the liabilities of that Section, and it shall not be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or under the Exchange Act, whether made
before or after the date hereof, except as expressly provided by
specific reference in such a filing.
By filing this Current Report on Form 8-K and furnishing the
information in this Item 7.01, the Company makes no admission as
to the materiality of Item 7.01 in this report or the
presentation attached hereto as Exhibit 99.1. The information
contained in the presentation is summary information that is
intended to be considered in the context of the Companys filings
with the SEC and other public announcements that the Company
makes, by press release or otherwise, from time to time. The
Company undertakes no duty or obligation to publicly update or
revise the information contained in this Item, although it may do
so from time to time as its management believes is appropriate.
Any such updating may be made through the filing of other reports
or documents with the SEC, through press releases or through
other public disclosure.
The Company cautions you that the presentation attached hereto as
Exhibit 99.1 contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act, as
amended. Statements in the presentation that are not purely
historical are forward-looking statements including, but not
limited to, the Companys ability to execute its business plan,
obtain regulatory approval for products under development, enter
into partnering agreements, realize revenue and pursue growth
opportunities, some of which are outside the control of the
Company.Readers and attendees are cautioned not to place undue
reliance on these forward-looking statements as actual results
could differ materially from the forward-looking statements
contained herein. Attendees are urged to read the risk factors
set forth in the Companys most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and its most
recent SEC filings.Company disclaims any intention to update this
presentation.
Section 9 Financial Statements and Exhibits
Item 9.01 Exhibits
Exhibit Number
Description
99.1
Corporate Presentation


About INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV)

Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

An ad to help with our costs